A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated influenza, to determine in-vivo antiviral activity. In this randomised, open-label, controlled, group sequential, adaptive, platform trial, we will compare the performance of available influenza antivirals, and those with potential activity, relative to the control (no treatment) and each other. AD ASTRA study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator

NCT Number	NCT05648448
Lead Sponsor	University of Oxford
Conditions	Influenza, Influenza, Human
Enrollment	3,000 participants
Start Date	2023-02-22
Primary Completion	2027-01-01 (estimated)
Study Completion	2027-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-14